367 related articles for article (PubMed ID: 19280746)
21. HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy.
Sabin CA
J Infect Dis; 2009 Jul; 200(1):8-10. PubMed ID: 19476436
[No Abstract] [Full Text] [Related]
22. Nucleoside analogues and HIV: the combined cost to mitochondria.
Cherry CL; Wesselingh SL
J Antimicrob Chemother; 2003 May; 51(5):1091-3. PubMed ID: 12668570
[No Abstract] [Full Text] [Related]
23. The seventh annual HIV drug guide.
Clifton CE; Vázquez E
Posit Aware; 2003; 14(1):36-60. PubMed ID: 12630375
[No Abstract] [Full Text] [Related]
24. Do your meds play well with others? A guide to HIV drug interactions.
Mehta S; Vázquez E
Posit Aware; 2011; 23(2):52-5. PubMed ID: 21796852
[No Abstract] [Full Text] [Related]
25. [Effective, safe and simple. The future means "once daily"].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():40-4. PubMed ID: 12043073
[No Abstract] [Full Text] [Related]
26. HIV treatment series. Treatment interruptions. Reviewing what we've learned so far.
Staszow K
Posit Aware; 2006; 17(3):37-40. PubMed ID: 16791962
[No Abstract] [Full Text] [Related]
27. [Which antiretroviral strategy to use in adults?].
Tonnerre P
Rev Infirm; 2003 Sep; (93):12-6. PubMed ID: 14593983
[No Abstract] [Full Text] [Related]
28. Editorial comment: treatment of acute HIV infection--uncertainties about best practice.
Kassutto S; Rosenberg ES
AIDS Read; 2005 May; 15(5):250-1. PubMed ID: 15900635
[No Abstract] [Full Text] [Related]
29. Advances in HIV treatment: the 3rd International AIDS Society Conference.
Boyle BA
AIDS Read; 2005 Oct; 15(10):552-7. PubMed ID: 16265770
[No Abstract] [Full Text] [Related]
30. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
Wepner U
MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
[No Abstract] [Full Text] [Related]
31. Side effects and complications. Swedes compare treatment switching with interruption.
TreatmentUpdate; 2005 Dec; 17(7):11. PubMed ID: 17225325
[No Abstract] [Full Text] [Related]
32. What does the term "HIV-associated lipodystrophy" mean?
Marcason W
J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
[No Abstract] [Full Text] [Related]
33. [Recommendations and prospects of antiretroviral therapy].
Draenert R; Goebel FD
Dtsch Med Wochenschr; 2001 May; 126(18):539-43. PubMed ID: 11381638
[No Abstract] [Full Text] [Related]
34. Switch therapy studies.
Mallon PW
J HIV Ther; 2001 May; 6(2):45-8. PubMed ID: 11505945
[No Abstract] [Full Text] [Related]
35. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
[No Abstract] [Full Text] [Related]
36. Current status of antiretroviral treatment interruption and intermittent therapy strategies.
Gallant JE
MedGenMed; 2002 Sep; 4(3):19. PubMed ID: 12466762
[No Abstract] [Full Text] [Related]
37. The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult.
Flanigan TP; Mitty JA
Clin Infect Dis; 2006 Jun; 42(11):1636-8. PubMed ID: 16652322
[No Abstract] [Full Text] [Related]
38. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Chang SY; Lin SW; Hung CC
Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
[No Abstract] [Full Text] [Related]
39. The causes of HIV antiviral treatment failure.
Clanon K
Focus; 2001 Jun; 16(7):5-6. PubMed ID: 11548663
[No Abstract] [Full Text] [Related]
40. [HAART influences the lipids].
Behrens G
MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
